Market Overview

Celgene Says ABRAXANE Demonstrates Statistically Significant Improvement

Share:
Related CELG
Is More M&A On The Way For Large-Cap Biotechs?
Morgan Stanley Raises Price Target On Celgene, Still Highlights Several Risks
Gilead Gets Wall Street Love After Q2 Earnings Beat (Investor's Business Daily)

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

Posted-In: News FDA

 

Related Articles (CELG)

Get Benzinga's Newsletters